Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com

ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024

NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

RMD ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of ResMed Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

ResMed Inc. (RMD) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why ResMed (RMD) is Poised to Beat Earnings Estimates Again

NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

Levi & Korsinsky Reminds ResMed Investors of the Ongoing Investigation into Potential Violations of Securities Laws - RMD

Evaluate the expected performance of ResMed (RMD) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Seeking Clues to ResMed (RMD) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

Shareholders that lost money on ResMed Inc.(RMD) should contact Levi & Korsinsky about Securities Fraud Investigation - RMD

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth

NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

ResMed Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by ResMed (RMD)

NEW YORK, NY / ACCESSWIRE / July 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws. On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023.

RMD STOCK ALERT: Levi & Korsinsky Notifies ResMed Inc. Investors of an Ongoing Investigation

American Water Works

AutoZone

Waste Management

Five reasonably priced stocks with solid growth history and a good chance of delivering earnings even if the economy softens.

5 Stocks With Solid Growth History and a Promising Outlook

Alphabet

NIKE

In a climate of stocks with negative analyst sentiment, JPMorgan Chase has issued a stark outlook for the S&P 500 index, projecting a significant decline by the end of the year. According to the bank's chief market strategist, the index is expected to fall to $4,200 — a more than 20% decrease from current levels.

Falling Knives: 3 Stocks Getting the Cold Shoulder From Analysts

ResMed is potentially undervalued, trading at a 31.65% discount from its 5Y average P/E ratio, with strong market leadership and untapped growth potential in OSA treatment. Projected 10-year EPS growth at 12.5% annually with a P/E of 25 gives a 2034 price target of $529.25 and an implied 10.9% CAGR, with potential for higher returns. Risks include competitive pressures from Philips' market re-entry, technological advances reducing OSA prevalence, and challenges in increasing diagnosis rates, yet ResMed's strong market position supports long-term investment.

ResMed: Potentially Undervalued Amid Increasing Sleep Apnea Awareness

SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, August 1, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024

RMD's competitive advantages in the sleep domain are durable, and its underlying business remains strong. It looks attractively valued based on future growth opportunities, resilient returns on capital, and potential for multiple expansions. A major advantage is the continued business expansion earning >15% on all capital used in operations with minimal reinvestment requirements to maintain its competitive position.

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

Badger Meter

Ingersoll-Rand

Leidos Hld

Stocks such as ResMed (RMD), Badger Meter (BMI), Leidos (LDOS) and Ingersoll Rand (IR) are currently exhibiting superb earnings growth.

4 Top Earnings Growth Stocks to Buy: RMD, BMI, LDOS, IR

Planet Fitness

Tempur Sealy International

When one thinks about safe stocks to buy, investors generally think of blue-chip large-cap companies such as Berkshire Hathaway (NYSE: BRK-A , NYSE: BRK-B ) or Microsoft (NASDAQ: MSFT ). However, manufacturers of beds, sleep apnea machines and proper lighting are participating in a $585 billion global sleep economy.

Sound Investments: 3 Stocks to Buy for a Good Night's Rest

Shares of ResMed, a maker of CPAP and other sleep-apnea airway machines, have dropped because of weight-loss developments. It's an overreaction.

ResMed Stock Is Down Because of GLP-1 Concerns. It Shouldn't Be.

Coinbase

NVIDIA

U.S. stocks were mixed, with the Dow Jones index gaining around 300 points on Monday.

ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday

Eli Lilly

Shares of medical device maker ResMed (RMD) are tumbling in intraday trading Monday as markets react to a pair of Phase 3 clinical trials from drugmaker Eli Lilly (LLY) released Friday that could have an impact on ResMed's future business.

Why a Pair of Eli Lilly Clinical Trials Sent ResMed Stock Tumbling

Shares of medical-device makers ResMed Inc. and Inspire Medical Systems Inc. tumbled on Monday after Eli Lilly & Co. said it has applied for regulatory approval of its weight-loss drug Zepbound to include treatment of sleep apnea.

Medical-device makers ResMed and Inspire slump after Lilly's Zepbound trial shows benefits for sleep apnea

Steelcase

SCS, BKNIY and RMD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 24, 2024.

Best Momentum Stock to Buy for June 24th

Eli Lilly is seeking FDA approval to expand the uses for its weight-loss drug Zepbound to include sleep apnea.

ResMed Stock Is Sinking. Blame Lilly's Zepbound Trials for Sleep Apnea.

Boston Scientific

Haemonetics

Lantheus Holdings

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.

4 Medical Product Stocks to Buy From a Recovering Industry

SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP 2024, the annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. Held in Houston, the event brought together scientific and medical experts focused on sleep health.

News for ResMed Stock (RMD)